Neumarker And Cortica Partner For Autism AI Research

The companies are using AI foundation models and clinical data to identify biomarkers for personalized autism care.

Updated on Oct. 15, 2026 in Autism

Isometric editorial illustration of a medical diagnostic lens and a neural lattice, representing precision medicine research. — Neumarker and Cortica have formed a strategic partnership to apply AI foundation models to clinical autism research in California. AI Illustration. Upload story photo >

Live Poll

Would you trust AI-driven analysis of your medical data to improve your personalized healthcare outcomes?

Neumarker and Cortica have entered a strategic collaboration to research autism care using AI-native brain intelligence platforms. The partnership aims to discover biomarkers that support personalized treatment for children with autism.

Why it matters

Clinicians currently have limited tools to predict how children with autism will respond to various treatments. This collaboration seeks to bridge that gap by applying precision medicine to the diverse clinical profiles found in neurodevelopmental care.

Cortica provides specialized care to over 20,000 patients annually and employs a staff of more than 2,300 clinicians. The research collaboration integrates this longitudinal clinical data with Neumarker's large-scale EEG foundation model.

The players

Neumarker

Based in Mountain View, this company develops large-scale EEG foundation models specifically designed for central nervous system medicine.

Cortica

Headquartered in San Diego, this organization provides comprehensive neurological therapies and support services for children with autism and developmental differences.

The details

The collaboration leverages Neumarker's AI-native brain intelligence platform to analyze de-identified patient data provided by Cortica. By combining this technical infrastructure with Cortica's clinical expertise, the project intends to accelerate the development of precision medicine tools.

2017: Cortica was established.
October 15, 2026: Neumarker and Cortica announced their strategic collaboration agreement.

Health Landscape

This partnership follows a growing industry pattern of using proprietary neural foundation models to interpret complex clinical EEG data for pediatric diagnostics. It represents a shift toward digitizing traditional neurological care through predictive AI modeling.

This research aims to eventually provide families with more predictable treatment pathways for children with diverse clinical profiles. While the partnership is currently in the data research phase, it seeks to improve the long-term personalization of medical interventions.

The takeaway

Precision medicine in autism care requires large datasets to translate complex neurological patterns into actionable treatment plans. Families should expect that data-driven diagnostics will play an increasing role in customizing developmental therapies over the coming years.